The ETV7 antibody is a key tool for studying the ETS variant transcription factor 7 (ETV7), a member of the ETS family of transcription factors involved in regulating gene expression during development, immunity, and cancer. ETV7. also known as TEL2 or ER74. plays dual roles in cellular processes. It is implicated in hematopoietic differentiation and immune regulation, but its dysregulation is linked to oncogenesis, particularly in leukemias, breast cancer, and glioblastoma. Structurally, ETV7 contains an N-terminal pointed (PNT) domain for protein interactions and a C-terminal ETS DNA-binding domain. Overexpression of ETV7 promotes cell proliferation, survival, and metastasis by modulating genes involved in cell cycle progression, apoptosis resistance, and epithelial-mesenchymal transition. It also interacts with pathways like STAT and MAPK, contributing to therapy resistance. Antibodies targeting ETV7 enable detection of its expression and localization via techniques like Western blot, immunohistochemistry, and immunofluorescence, aiding in mechanistic studies and clinical correlations. Research using ETV7 antibodies has highlighted its potential as a biomarker or therapeutic target, especially in cancers with aberrant ETS signaling. Additionally, ETV7's role in antiviral responses, where it suppresses interferon production, underscores its relevance in infection and immunity. These antibodies thus serve as critical reagents for unraveling ETV7's multifaceted roles in health and disease.